Stem Cell Therapy for Chronic Fatigue Syndrome: A Promising Approach
DOI:
https://doi.org/10.58344/jws.v3i11.1231Keywords:
chronic fatigue syndrome, immunomodulation, mesenchymal stem cells, regenerative medicine, stem cell therapyAbstract
Chronic Fatigue Syndrome (CFS), or Myalgic Encephalomyelitis (ME), is a debilitating condition marked by persistent fatigue, cognitive dysfunction, and chronic pain, severely affecting quality of life. This study explores the potential of mesenchymal stem cell (MSC) therapy as an innovative treatment for CFS. Using a qualitative descriptive design and case studies, data were gathered through interviews, medical record reviews, and observations of patients undergoing MSC therapy. The findings revealed significant improvements in fatigue, cognitive function, and physical well-being, with participants reporting better memory, concentration, reduced pain, and improved daily functioning. While some sleep disturbances persisted, their severity was reduced. These results highlight the potential of MSC therapy to alleviate CFS symptoms and enhance quality of life. Despite its promise, challenges such as high costs, regulatory hurdles, and the need for standardized protocols persist. Further research is required to confirm long-term efficacy and safety, contributing to the growing evidence for regenerative medicine in treating chronic conditions like CFS.
References
Abusalah, M. A. H., Abd Rahman, E. N. S. E., & Choudhary, O. P. (2024). Evolving trends in stem cell therapy: an emerging and promising approach against various diseases. International Journal of Surgery, 10–1097.
Al-Dhalimy, A. M. B., Salim, H. M., Shather, A. H., Naser, I. H., Hizam, M. M., & Alshujery, M. K. (2023). The pathological and therapeutically role of mesenchymal stem cell (MSC)-derived exosome in degenerative diseases; Particular focus on LncRNA and microRNA. Pathology Research and Practice, 250. https://doi.org/10.1016/j.prp.2023.154778
Bested, A. C., & Marshall, L. M. (2015). Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians. Reviews on Environmental Health, 30(4), 223–249.
Carruthers, B. M., Jain, A. K., De Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., Bested, A. C., Flor-Henry, P., Joshi, P., & Powles, A. C. P. (2003). Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome, 11(1), 7–115.
Cockshell, S. J., & Mathias, J. L. (2010). Cognitive functioning in chronic fatigue syndrome: a meta-analysis. Psychological Medicine, 40(8), 1253–1267.
Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C. T., Arcos-Burgos, M., & Lidbury, B. A. (2019). Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics, 9(3), 91.
Cuerquis, J., Romieu-Mourez, R., François, M., Routy, J.-P., Young, Y. K., Zhao, J., & Eliopoulos, N. (2014). Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-? and tumor necrosis factor-? stimulation. Cytotherapy, 16(2), 191–202.
Derafsh, E., Ebrahimzadeh, F., Kahrizi, M. saeed, Kayedi, M., Shojaei, N., Rahimi, S., Alesaeidi, S., & Ghafouri, K. (2023). The therapeutic effects of mesenchymal stem cell (MSCs) exosomes in covid-19 disease; Focusing on dexamethasone therapy. Pathology Research and Practice, 251. https://doi.org/10.1016/j.prp.2023.154815
Elder, E., Johnston, A. N. B., Wallis, M., & Crilly, J. (2020). The demoralisation of nurses and medical doctors working in the emergency department: A qualitative descriptive study. International Emergency Nursing, 52, 100841.
Fan, X.-L., Zhang, Y., Li, X., & Fu, Q.-L. (2020). Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cellular and Molecular Life Sciences, 77, 2771–2794.
Gou, Y., Huang, Y., Luo, W., Li, Y., Zhao, P., Zhong, J., Dong, X., Guo, M., Li, A., Hao, A., Zhao, G., Wang, Y., Zhu, Y., Zhang, H., Shi, Y., Wagstaff, W., Luu, H. H., Shi, L. L., Reid, R. R., … Fan, J. (2024). Adipose-derived mesenchymal stem cells (MSCs) are a superior cell source for bone tissue engineering. Bioactive Materials, 34, 51–63. https://doi.org/10.1016/j.bioactmat.2023.12.003
Hoban, D. B., Howard, L., & Dowd, E. (2015). GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson’s disease. Neuroscience, 303, 402–411.
Jason, L. A., & Sunnquist, M. (2018). The development of the DePaul Symptom Questionnaire: Original, expanded, brief, and pediatric versions. Frontiers in Pediatrics, 6, 409729.
Karavitaki, N., & Prete, A. (2024). therapy of glucocorticoid-induced adrenal insufficiency. European Journal of Endocrinology, 190, G25–G51.
Kodama, J., Wilkinson, K. J., & Otsuru, S. (2022). MSC-EV therapy for bone/cartilage diseases. Bone Reports, 17. https://doi.org/10.1016/j.bonr.2022.101636
Marshall-Gradisnik, S., Huth, T., Chacko, A., Johnston, S., Smith, P., & Staines, D. (2016). Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. The Application of Clinical Genetics, 39–47.
Mehrabadi, A. Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M. A., & Ghaleh, H. E. G. (2022). Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomedicine & Pharmacotherapy, 146, 112512.
Nguyen, T., Johnston, S., Clarke, L., Smith, P., Staines, D., & Marshall-Gradisnik, S. (2017). Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clinical & Experimental Immunology, 187(2), 284–293.
Rahal, A., Kumar, A., Singh, V., Yadav, B., Tiwari, R., Chakraborty, S., & Dhama, K. (2014). Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed Research International, 2014(1), 761264.
Rowe, P. C., Underhill, R. A., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M. S., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: a primer. Frontiers in Pediatrics, 5, 121.
Sapag, M. A., Herrera-Luna, Y., Lara-Barba, E., Pradenas, C., García, C., Oyarce, S., Bustamante-Barrientos, F., Elizondo-Vega, R., Altamirano, C., Ortoloff, A., Figueroa-Valdés, A. I., Alcayaga-Miranda, F., Khoury, M., Matas, J., Barahona, M., Djouad, F., Toledo, J., Vega-Letter, A., & Luz-Crawford, P. (2024). sEVs FROM METABOLICALY REPROGRAMMED UC-MSCs AS A POTENTIAL MULTIFUNCIONAL ACELLULAR THERAPY FOR OSTEOARTHRITIS. Cytotherapy, 26(6), S30. https://doi.org/10.1016/j.jcyt.2024.03.051
Tomas, C., Brown, A., Strassheim, V., Elson, J., Newton, J., & Manning, P. (2017). Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PloS One, 12(10), e0186802.
Vaheb, S., Afshin, S., Ghoshouni, H., Ghaffary, E. M., Farzan, M., Shaygannejad, V., Thapa, S., Zabeti, A., & Mirmosayyeb, O. (2024). Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 87. https://doi.org/10.1016/j.msard.2024.105681
Zhang, Y., Ge, X., Guo, X.-J., Guan, S., Li, X., Gu, W., & Xu, W. (2017). Bone marrow mesenchymal stem cells inhibit the function of dendritic cells by secreting galectin?1. BioMed Research International, 2017(1), 3248605.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Deby Susanti Pada Vinski Pada Vinski, Svetlana Trofimova, Jaime Rodriguez Quintosa, Andi Kurniawan Nugroho, CA Schroeter, Stevan Jovanovic
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International. that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
